What You Should Know
- Medical device regulatory and certification platform Scarlet raises $50M in Series B funding round led by Headline, with participation from new investor Notion Capital and existing backers Atomico, Creandum, Kindred Capital, and Entrepreneurs First; Nancy Xiao McLaughlin, Partner at Headline, joins Scarlet’s Board of Directors.
- Targets an acute regulatory bottleneck in digital health innovation: machine learning teams can train and validate an AI diagnostic model in weeks, yet legacy certification bodies typically subject developers to 12 to 18 months of review for initial market clearance, followed by six to eight months of administrative delay for minor algorithmic updates.
- Operates as a government-designated certification body: out of the approximately 52 notified bodies designated under the European Union Medical Device Regulation (EU MDR), Scarlet is the only one exclusively specialized in software and artificial intelligence, built to support agile, iterative continuous deployment (CI/CD) pipelines.
Triple-Designated Statutory Authority
Unlike regulatory consulting firms or compliance software platforms that merely format submission documents, Scarlet operates as a formal, government-designated statutory auditing and certification body. Among the roughly 52 officially designated certification bodies under the European Union Medical Device Regulation, Scarlet is the sole entity purpose-built and designated exclusively for Software as a Medical Device and artificial intelligence.
The company also holds formal statutory designation from the UK Medicines and Healthcare products Regulatory Agency to issue UKCA markings for medical software, alongside accreditation under the U.S. Food and Drug Administration’s Third-Party Review Program, which authorizes Scarlet to conduct substantive regulatory reviews of eligible 510(k) premarket notifications. Founded in 2021 by former Babylon Health AI engineers James Dewar and Jamie Cox, the company spent its initial three years in rigorous collaboration with international regulatory agencies to secure full formal accreditation before issuing its first commercial certificates.
Operating Architecture: Modernizing Technical File Audits
Scarlet replaces manual, paper-heavy regulatory dossiers with an AI-enabled certification operating system designed for agile software sprints. Medical device manufacturers upload clinical evaluation reports, verification and validation data, risk management files, and software architecture artifacts in any format. Scarlet’s ingestion layer parses and correlates technical documentation against international harmonized standards.
Technical assessments are conducted by specialized software and clinical AI reviewers who evaluate machine learning architectures, training and testing distribution shifts, and cybersecurity controls with software-native speed. Every audit finding, validation trace, and conformity decision is systematically evidenced within an immutable audit trail, providing competent authorities and regulatory bodies with full visibility into the technical reasoning behind certification decisions.
Operating on a recurring enterprise subscription model, Scarlet covers ongoing post-market surveillance, mandatory annual quality management system audits, and continuous product changes. This framework enables manufacturers to clear bi-weekly model iterations and algorithmic updates without filing duplicative, multi-month re-submissions.
Enterprise Client Roster and Market Validation
Scarlet’s AI-native assessment platform serves leading digital health enterprises, consumer giants, acute health systems, and high-volume clinical AI providers. In scaled consumer health, it powers regulatory certification for Flo Health, the women’s health application supporting over 500 million downloads. Across diagnostic and clinical specialties, the platform evaluates algorithmic oncology software such as skin cancer detection specialist Skin Analytics, as well as acute enterprise imaging infrastructure for U.S. radiology platform DeepHealth.
Public institutional care infrastructure is represented by deployments with NHS England, while clinical voice and agentic documentation platforms include ambient scribes Heidi Health and Tandem, both of which recently completed nine-figure Series B financing rounds. The operational advantage of this agile framework is reflected in deployments like digital physiotherapy platform Flok Health, which utilizes Scarlet to deploy validated clinical updates to its regulated medical device twice per month—an iteration velocity previously unachievable under legacy European Notified Bodies.
Capital Allocation and Global Expansion Strategy
The $50 million Series B injection will be deployed to broaden Scarlet’s international footprint and engineering capabilities. Geographically, the company is establishing dedicated operational hubs across the United States and the Asia-Pacific region to support cross-border software-as-a-medical-device clearance pipelines.
Scarlet will also expand its internal roster of specialized machine learning auditors, bio-engineers, and regulatory clinicians. Furthermore, the company plans to broaden its certification portfolios to cover emergent multimodal foundation models, autonomous diagnostic agent frameworks, and generative clinical reasoning tools.
